BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33022056)

  • 1. Development and Validation of the Nasal Outcome Score for Epistaxis in Hereditary Hemorrhagic Telangiectasia (NOSE HHT).
    Peterson AM; Kallogjeri D; Spitznagel E; Chakinala MM; Schneider JS; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):999-1005. PubMed ID: 33022056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
    Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Psychometric Validity of the Epistaxis Severity Score: Internal Consistency and Test-Retest Reliability.
    Gong AJ; Bolsegui ML; Lee EE; Mathai SC; Weiss CR
    Am J Rhinol Allergy; 2024 Jan; 38(1):38-46. PubMed ID: 37822162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia.
    Yin LX; Reh DD; Hoag JB; Mitchell SE; Mathai SC; Robinson GM; Merlo CA
    Laryngoscope; 2016 May; 126(5):1029-32. PubMed ID: 26393959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
    Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
    JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) - Study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial.
    Andorfer KEC; Seebauer CT; Koller M; Zeman F; Berneburg M; Fischer R; Vielsmeier V; Bohr C; Kühnel TS
    Clin Hemorheol Microcirc; 2022; 80(3):307-315. PubMed ID: 34864649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial.
    Dupuis-Girod S; Pitiot V; Bergerot C; Fargeton AE; Beaudoin M; Decullier E; Bréant V; Colombet B; Philouze P; Faure F; Letievant JC
    Sci Rep; 2019 Aug; 9(1):11986. PubMed ID: 31427745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT).
    Lee JM; Wu V; Faughnan ME; Lasso A; Figol A; Kilty SJ
    J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):48. PubMed ID: 31615556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new endoscopic staging system for hereditary hemorrhagic telangiectasia.
    Reh DD; Yin LX; Laaeq K; Merlo CA
    Int Forum Allergy Rhinol; 2014 Aug; 4(8):635-9. PubMed ID: 24782401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First experiences with an individual nasal olive in patients with hereditary haemorrhagic telangiectasia (HHT).
    Al Kadah B; Papaspyrou G; Schneider M; Schick B
    Eur Arch Otorhinolaryngol; 2015 Jan; 272(1):117-22. PubMed ID: 24854232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentraxin 3 level is elevated in hereditary hemorrhagic telangiectasia and reflects the severity of disease-associated epistaxis.
    Steineger J; Ueland T; Aukrust P; Michelsen A; Osnes T; Heimdal K; Dheyauldeen S
    Laryngoscope; 2019 Jan; 129(1):E44-E49. PubMed ID: 30329172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An epistaxis severity score for hereditary hemorrhagic telangiectasia.
    Hoag JB; Terry P; Mitchell S; Reh D; Merlo CA
    Laryngoscope; 2010 Apr; 120(4):838-43. PubMed ID: 20087969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sinonasal quality of life outcomes following laser treatment of epistaxis related to hereditary hemorrhagic telangiectasia.
    Kuan EC; Peng KA; Thompson CF; Suh JD; Wang MB
    Lasers Med Sci; 2017 Apr; 32(3):527-531. PubMed ID: 28116537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal bevacizumab injections improve quality of life in HHT patients.
    Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
    Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Beta-Blockers in Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review.
    Albarki H; Rimmer J
    Am J Rhinol Allergy; 2022 Nov; 36(6):890-896. PubMed ID: 35929049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT).
    Zarrabeitia R; Fariñas-Álvarez C; Santibáñez M; Señaris B; Fontalba A; Botella LM; Parra JA
    Health Qual Life Outcomes; 2017 Jan; 15(1):19. PubMed ID: 28114930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical application of timolol decreases the severity and frequency of epistaxis in patients who have previously undergone nasal dermoplasty for hereditary hemorrhagic telangiectasia.
    Ichimura K; Kikuchi H; Imayoshi S; Dias MS
    Auris Nasus Larynx; 2016 Aug; 43(4):429-32. PubMed ID: 26739947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of epistaxis severity score for hereditary hemorrhagic telangiectasia in Japan.
    Hayama M; Maeda Y; Shikina T; Tatehara S; Inokuchi G; Hoag JB; Sato T; Obata S; Nakatani A; Amano Y; Hida E; Nibu KI; Inohara H
    Auris Nasus Larynx; 2022 Jun; 49(3):415-420. PubMed ID: 34857410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia.
    Silva BM; Hosman AE; Devlin HL; Shovlin CL
    Laryngoscope; 2013 May; 123(5):1092-9. PubMed ID: 23404156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal closure for the treatment of epistaxis secondary to hereditary hemorrhagic telangiectasia.
    Sena Esteves S; Cardoso C; Silva A; Abrunhosa J; Almeida E Sousa C
    Acta Otorrinolaringol Esp; 2016; 67(6):345-348. PubMed ID: 27079134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.